

# **ARGENX AND ABBVIE ARGX-115 COLLABORATION**

**21 April 2016**



## Disclaimer

THIS PRESENTATION IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. BY ATTENDING THE MEETING WHERE THIS PRESENTATION IS MADE YOU AGREE TO BE BOUND BY THE FOLLOWING TERMS AND CONDITIONS. THIS PRESENTATION, WHICH HAS BEEN PREPARED BY ARGEN-X N.V. (THE “COMPANY”) MAY NOT BE REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS.

For the purposes of this notice, “presentation” means this document, its contents or any part of it, any question or answer session and any written or oral material discussed or distributed in connection with this presentation either before, after or during the presentation meeting.

This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer to sell, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities of the Company, nor shall it or any part of it form the basis of or be relied upon in connection with or act as any inducement to enter into any contract or commitment or investment decision whatsoever. This presentation is not an offer of securities for sale in the United States. The securities of the Company have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration.

This presentation is made available on the express understanding that it does not contain all information that may be required to evaluate, and will not be used by the attendees/recipients in connection with, the purchase of or investment in any securities of the Company. This presentation is accordingly not intended to form the basis of any investment decision and does not

constitute or contain (express or implied) any recommendation by the Company or any of its directors, officers, employees, agents, affiliates or advisers.


Certain information in this presentation is based on management estimates. Such estimates have been made in good faith and represent the current beliefs of applicable members of management. Those management members believe that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete.

This presentation may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company’s actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

## Agenda

- Introduction
- ARGX-115 Partnership with AbbVie
- Q&A

# Introduction





## Rich pipeline with multiple proprietary programs

- Oncology & severe autoimmune diseases
- 4 products in clinical phase

abbvie

## Strategic alliances with premier pharma partners

- Industrial partners
- Innovative Access Program

ARGX-115 is the first success under argenx's IAP and results from pioneering work in the immuno-oncology field by UCL/de Duve Institute



## Competitive technology suite

- Antibodies with differentiated modes of action
- Based on llama immune system and unique Fc engineering




## Financial strength

- Strong cash position (€ 54.3Mio Feb 2016)
- € 1.4B potential future income from partnerships


## Generating differentiated antibody product candidates...



## ... towards Phase II value inflection point




# Unique technology platform: multiple modes of action



- SIMPLE Antibody™: Unlock novel and complex targets
- NHance®, ABDEG™, POTELLIGENT®: Enhance SIMPLE Antibody™ leads
- Multiple layers of IP protection in place until 2028-2033 (excluding any PTE)

## GARP: a novel immune checkpoint



- GARP upregulated specifically on surface of Tregs only
- GARP presents and activates latent TGF-β1, activating Tregs and suppressing Teff cells
- SIMPLE Antibody™ hitting unique, patented epitope on GARP
- GARP blockade sufficient for MoA – no Treg depletion
- Graft-versus-host-disease model delivered convincing PoC




Cuende et al., 2015, Science Translational Medicine



# ARGX-115

## Partnership with AbbVie

















# Rich pipeline approaching major value inflection points

- Cancer immunotherapy

- Cancer metastasis

- Autoimmune diseases

- Non-dilutive income

Drug Candidate	Indication	Preclinical	Phase 1	Phase 2	Owner-ship
ARGX-110 (CD70)	Blood cancers <i>TCL</i>				Wholly owned
ARGX-110 (CD70)	Solid tumors				
ARGX-115 (GARP)	Cancer immunotherapy				
ARGX-111 (c-MET)	Solid tumors Blood cancers				
ARGX-113 (FcRn)	Autoimmunity <i>Myasthenia gravis</i>				
ARGX-110 (CD70)	Autoimmunity				
Discovery	Autoimmunity Cancer	<i>multiple</i>			
	Autoimmunity Cancer				Partnered
	Undisclosed				
	Chronic inflammation				
	Undisclosed				

# AbbVie Option Deal for ARGX-115: Key Elements

- **Financial terms**

- \$40MM upfront
- Preclinical milestones 2x \$10MM
- Up to \$625MM development, regulatory and commercial milestones
- Tiered, up to double-digit royalty payments on net sales

- **Deal Structure**



- Responsible for delivering IND data package
- May combine ARGX-115 with its own pipeline mAbs
- Co-promotion right to GARP-targeted products (EU/Swiss Economic Area)



- Option to exclusive development and commercialization license
- Will fund further GARP-related research for initial period of 2years, subject to argenx reaching pre-determined preclinical stage milestone
- Right to license additional therapeutic programs resulting from this research in return for additional milestone and royalty payments

# Q&A

